+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies



Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies



Multiple Sclerosis 13(4): 561-562



The Sonya Slifka Longitudinal Multiple Sclerosis (MS) Study follows a population-based cohort of approximately 2000 people with MS to study demographic and clinical characteristics, use and cost of health services, provider and treatment characteristics, neurological, economic, and psychosocial outcomes. We examined key indicators of access to health care and found that the majority of participants had health insurance, a usual source of care, and access to specialty care. Nevertheless, 3.8% did not have health insurance which, with application of sampling weights, corresponds to approximately 7000 people with MS in the US population. Even with insurance, population-based estimates indicated that substantial numbers of people with MS have plans that pay nothing toward prescription medication, limit their access to specialists, and restrict their choice of hospitals and providers. Some 9% of the sample, corresponding to 15,800 people with MS, did not have a usual source of MS care; 11.8% or 17,300 people did not have a usual source of general health care; and 31% or 57,400 people did not see the specialists that they or their physicians wanted them to see. Further, 10.5% or 19,400 people reported difficulty obtaining prescription medication, 4.1% or 7600 people encountered obstacles accessing medical care, and 2.4% or 4500 people could not obtain the mental health services they needed. Finally, out-of-pocket health care expenditures were twice those found for the general population. Two-thirds of study participants (representing almost 70,000 people) chose their MS care providers because they were neurologists or MS specialists, creating a demand that almost certainly exceeds current supply.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 016335854

Download citation: RISBibTeXText

PMID: 17615626

DOI: 10.1177/1352458506070897


Related references

Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clinica Chimica Acta; International Journal of Clinical Chemistry 373(1-2): 180-1; Author Reply 182, 2006

Preanalytical conditions and circulating matrix metalloproteinases. Transplantation 79(6): 745-746, 2005

Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers. Transplantation 79(6): 744-744, 2005

Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. Clinical Chemistry and Laboratory Medicine 44(4): 500-502, 2006

Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood. Journal of Rheumatology 34(4): 890-2; Author Reply 892, 2007

Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clinical Chemistry 49(11): 1956-1957, 2003

Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data. Multiple Sclerosis 15(11): 1372-3; Author Reply 1374-5, 2010

Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling. European Journal of Cardio-Thoracic Surgery 33(5): 944; Author Reply 945-944; Author Reply 945, 2008

Prediction of malignant transformation of hydatidiform mole by mRNA determination of matrix metalloproteinases and tissue inhibitor of metalloproteinases. Zhonghua Fu Chan Ke Za Zhi 35(9): 547-550, 2002

Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37(1): 235-239, 2005

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level. Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, February 19, 2004

Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Laboratory Investigation; A Journal of Technical Methods and Pathology 81(4): 613-627, 2001

Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arteriosclerosis, Thrombosis, and Vascular Biology 28(4): 611-614, 2008